AI App Detects Skin Cancer with 99.8% Accuracy, Slashing NHS Wait Times

For overburdened health systems like the NHS, where dermatology waits can stretch months, the ability to rule out skin cancer at a pharmacy in seconds is a game-changer. Derm AI’s 99.8% sensitivity means GPs can confidently discharge low-risk lesions, reserving specialist time for the patients who truly need it. This isn’t just an innovation in diagnostics—it’s a capacity multiplier that could reshape primary care workflows.

The UK’s NHS is poised for a dramatic reduction in dermatology waiting lists with the latest iteration of Derm AI, a smartphone-based artificial intelligence tool developed by British firm Skin Analytics. Having already detected 20,000 cancers in over 230,000 patients in an earlier version that required a special camera lens, the new iteration has secured the highest level of medical device approval in Europe and eliminates the need for any additional hardware. This means patients can receive a clinical-grade skin cancer assessment in seconds at a GP surgery or pharmacy, without a hospital appointment. The timing is critical: melanoma rates in the UK have reached a record high, with new diagnoses climbing almost a third in the past decade. Every year, about 20,000 people develop melanoma, leading to more than 2,300 deaths. The AI has demonstrated 99.8% effectiveness in detecting melanomas, a figure that places it near the accuracy of expert dermatologists.

“

Derm AI’s 99.8% sensitivity means GPs can confidently discharge low-risk lesions, reserving specialist time for the patients who truly need it.

The technology addresses a pressing capacity gap. Primary care providers often struggle to triage the vast number of skin lesion referrals, many of which are benign. By providing a definitive negative for lesions of no concern, Derm AI allows specialists to focus on high-risk cases. Dr Alexandra Kemp, a consultant dermatologist at Amersham Hospital, confirmed that since introducing the earlier version of Derm, there has been a marked improvement in clinical capacity and care efficiency. The software is trained on thousands of images with known diagnoses, enabling it to identify suspicious patterns with high precision.

Market implications extend beyond the NHS. The removal of the special lens attachment transforms Derm AI from a niche hospital tool into a scalable population-health solution. Pharmacies and even telemedicine providers could integrate the app, creating a new front door for dermatology. For Skin Analytics, the EU approval provides a regulatory springboard into other markets, including potential FDA recognition in the US. The business model may shift from software licenses to value-based contracts, where health systems pay for reduced unnecessary referrals and earlier cancer detection.